CuraGen and TopoTarget Leukemia Drug Enters Phase II
Posted on: Wednesday, 7 June 2006, 12:00 CDT
CuraGen and TopoTarget have initiated patient dosing in a phase II clinical trial evaluating the activity of PXD101, a small molecule histone deacetylase inhibitor, for the treatment of acute myelogenous leukemia.
This trial is being sponsored by the US National Cancer Institute (NCI) under an agreement with CuraGen and will be conducted at multiple sites in the US.
Up to 55 acute myelogenous leukemia (AML) patients will be enrolled in the phase II trial and will receive three week cycles of PXD101 administered by intravenous infusion. Patients demonstrating complete or partial response will continue to receive treatment with PXD101 until disease progression. The primary endpoint for the study is response rate, with secondary endpoints measuring overall survival and time to treatment failure.
The trial is an open-label study being led by Dr Kenneth Foon, director of clinical investigations at the University of Pittsburgh Cancer Institute, in collaboration with Dr Mark Kirschbaum, director of new drug development at City of Hope in Duarte, California.
"The research we have conducted on HDAC (histone deacetylase) inhibitors at City of Hope suggests that agents like PXD101 affect many of the critical pathways cancer cells use for survival," stated Dr Kirschbaum. "Based on these intriguing results we have initiated patient treatment with PXD101 and look forward to evaluating the role of this HDAC inhibitor for the treatment of AML."
Source: Datamonitor
Related Articles
- FDA Grants Orphan Drug Status to Reata's RTA 402 for Treatment of Pancreatic Cancer
- Examine the Phase III Clinical Data Recently Released About ACAPODENE in the Treatment of Prostate Cancer
- Supratek's Lead Compound SP1049C is Granted Orphan Drug Designation for the Treatment of Gastric Cancer.
- New Studies Unveiled at ASTRO's 49th Annual Meeting of Radiation Oncology Specialists Support the Effectiveness of IsoRay Medical's Proxcelan(TM) for the Treatment of Prostate Cancer
- Genomic Predictors Report Likely Response to Multiple Treatments in Breast Cancer
- AmpliMed Receives Orphan Drug Designation for Amplimexon in the Treatment of Ovarian Cancer
- New Study Confirms Value of Vitamin D Supplementation in the Adjunctive Treatment of Prostate Cancer
- New Targeted Treatment for Prostate Cancer Available in Chicago
- Streamlined Treatment for Lung Cancer Patients Demanded
- Taxotere(R) (Docetaxel) Receives 2 New European Approvals For Treatment of Breast Cancer
 |
 |
User Comments (0)
RSS Feeds